AKTIENANLEIHE - EXPRESS PROTECT - BIONTECH ADR Share Price

Certificat

DE000HVB60P6

Market Closed - Deutsche Boerse AG 18:39:50 24/05/2024 BST
55.08 EUR -9.85% Intraday chart for AKTIENANLEIHE - EXPRESS PROTECT - BIONTECH ADR
Current month+21.93%
1 month+23.51%
Date Price Change
24/05/24 55.08 -9.85%
23/05/24 61.1 +1.19%
22/05/24 60.38 +18.58%
21/05/24 50.92 -2.17%
20/05/24 52.05 +0.29%

Delayed Quote Deutsche Boerse AG

Last update May 24, 2024 at 06:39 pm

More quotes

Static data

Product typeReverse Convertibles
Buy / SellCALL
Underlying BIONTECH SE
IssuerLogo Issuer UniCredit UniCredit
WKN HVB60P
ISINDE000HVB60P6
Date issued 16/11/2021
Strike 235 $
Maturity 11/11/2024 (171 Days)
Parity 0.24 : 1
Emission price 100
Emission volume N/A
Settlement both
Currency EUR

Technical Indicators

Highest since issue 101.9
Lowest since issue 46.9

Company Profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sector
-
More about the company

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: BioNTech SE

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
89.32 EUR
Average target price
104.7 EUR
Spread / Average Target
+17.22%
Consensus